PMID- 28932089
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20211204
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 23
IP  - 32
DP  - 2017 Aug 28
TI  - Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney 
      transplantation recipients with hepatitis C virus infection.
PG  - 5969-5976
LID - 10.3748/wjg.v23.i32.5969 [doi]
AB  - AIM: To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for 
      kidney transplantation (KT) patients with hepatitis C virus (HCV) infection. 
      METHODS: This study enrolled a prospective cohort of consecutive Chinese KT 
      patients with HCV infection. They were given sofosbuvir combined with 
      daclatasvir, with or without ribavirin. They were monitored regularly during and 
      after the treatment. RESULTS: Six patients were recruited in our prospective 
      study cohort. All patients were male and naive to direct-acting antiviral 
      treatment. The treatment duration was 12 wk. Most patients (4/6) were infected 
      with HCV genotype 1b. HCV RNA was undetectable at week 4 after treatment and at 
      the end of treatment in all patients. Sustained virological response rate at 12 
      wk was 100% (6/6). Two patients had to accept a half dose of sofosbuvir due to 
      serum creatinine elevation during treatment. Kidney function in the remaining 
      patients was stable. No serious adverse events (AEs) were observed. No patient 
      discontinued antiviral therapy due to side effects. CONCLUSION: Sofosbuvir and 
      daclatasvir for treatment of KT recipients with HCV infection are highly 
      efficient and safe. Patients tolerated the medications well, and no serious AEs 
      were observed. Larger prospective cohort studies are needed to validate these 
      results.
FAU - Xue, Yan
AU  - Xue Y
AD  - Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong 
      University, Jinan 250033, Shandong Province, China.
FAU - Zhang, Li-Xin
AU  - Zhang LX
AD  - Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong 
      University, Jinan 250033, Shandong Province, China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong 
      University, Jinan 250033, Shandong Province, China. wlcrb@sdu.edu.cn.
FAU - Li, Tao
AU  - Li T
AD  - Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong 
      University, Jinan 250033, Shandong Province, China.
FAU - Qu, Yun-Dong
AU  - Qu YD
AD  - Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong 
      University, Jinan 250033, Shandong Province, China.
FAU - Liu, Feng
AU  - Liu F
AD  - Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong 
      University, Jinan 250033, Shandong Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Antiviral Agents)
RN  - 0 (Carbamates)
RN  - 0 (Imidazoles)
RN  - 0 (Pyrrolidines)
RN  - 0 (RNA, Viral)
RN  - 49717AWG6K (Ribavirin)
RN  - HG18B9YRS7 (Valine)
RN  - LI2427F9CI (daclatasvir)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Carbamates
MH  - China
MH  - Drug Therapy, Combination/methods
MH  - Graft Rejection/prevention & control/virology
MH  - Hepacivirus/genetics
MH  - Hepatitis C, Chronic/complications/*drug therapy/virology
MH  - Humans
MH  - Imidazoles/*therapeutic use
MH  - Kidney Transplantation/*adverse effects
MH  - Liver Cirrhosis/prevention & control/virology
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Pyrrolidines
MH  - RNA, Viral/isolation & purification
MH  - Ribavirin/therapeutic use
MH  - Sofosbuvir/*therapeutic use
MH  - Transplant Recipients
MH  - Treatment Outcome
MH  - Valine/analogs & derivatives
PMC - PMC5583582
OTO - NOTNLM
OT  - Daclatasvir
OT  - Direct-acting antivirals
OT  - Hepatitis C virus
OT  - Kidney transplantation
OT  - Sofosbuvir
COIS- Conflict-of-interest statement: All authors have no conflicts of interest.
EDAT- 2017/09/22 06:00
MHDA- 2018/05/22 06:00
PMCR- 2017/08/28
CRDT- 2017/09/22 06:00
PHST- 2017/05/31 00:00 [received]
PHST- 2017/07/03 00:00 [revised]
PHST- 2017/07/12 00:00 [accepted]
PHST- 2017/09/22 06:00 [entrez]
PHST- 2017/09/22 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/08/28 00:00 [pmc-release]
AID - 10.3748/wjg.v23.i32.5969 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2017 Aug 28;23(32):5969-5976. doi: 
      10.3748/wjg.v23.i32.5969.